215 related articles for article (PubMed ID: 32039355)
1. Global progress on the elimination of viral hepatitis as a major public health threat: An analysis of WHO Member State responses 2017.
Smith S; Harmanci H; Hutin Y; Hess S; Bulterys M; Peck R; Rewari B; Mozalevskis A; Shibeshi M; Mumba M; Le LV; Ishikawa N; Nolna D; Sereno L; Gore C; Goldberg DJ; Hutchinson S
JHEP Rep; 2019 Aug; 1(2):81-89. PubMed ID: 32039355
[TBL] [Abstract][Full Text] [Related]
2. Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017.
Lazarus JV; Stumo SR; Harris M; Hendrickx G; Hetherington KL; Maticic M; Jauffret-Roustide M; Tallada J; Simojoki K; Reic T; Safreed-Harmon K;
J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25052. PubMed ID: 29633562
[TBL] [Abstract][Full Text] [Related]
3. Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines.
Malik F; Bailey H; Chan P; Collins IJ; Mozalevskis A; Thorne C; Easterbrook P
JHEP Rep; 2021 Apr; 3(2):100227. PubMed ID: 33665586
[TBL] [Abstract][Full Text] [Related]
4. The civil society monitoring of hepatitis C response related to the WHO 2030 elimination goals in 35 European countries.
Maticic M; Pirnat Z; Leicht A; Zimmermann R; Windelinck T; Jauffret-Roustide M; Duffell E; Tammi T; Schatz E
Harm Reduct J; 2020 Nov; 17(1):89. PubMed ID: 33213481
[TBL] [Abstract][Full Text] [Related]
5. Barriers and Strategies for Hepatitis B and C Elimination in Pakistan.
Qureshi H; Mahmood H; Sabry A; Hermez J
J Infect Dis; 2023 Sep; 228(Suppl 3):S204-S210. PubMed ID: 37703344
[TBL] [Abstract][Full Text] [Related]
6. Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey.
Spina A; Eramova I; Lazarus JV
BMC Infect Dis; 2014; 14 Suppl 6(Suppl 6):S15. PubMed ID: 25252705
[TBL] [Abstract][Full Text] [Related]
7. Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Bulterys M; Ball A; Hirnschall G
Lancet Glob Health; 2019 Sep; 7(9):e1180-e1188. PubMed ID: 31353061
[TBL] [Abstract][Full Text] [Related]
8. Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020.
Scott N; Ólafsson S; Gottfreðsson M; Tyrfingsson T; Rúnarsdóttir V; Hansdottir I; Hernandez UB; Sigmundsdóttir G; Hellard M
J Hepatol; 2018 May; 68(5):932-939. PubMed ID: 29274408
[TBL] [Abstract][Full Text] [Related]
9. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
[TBL] [Abstract][Full Text] [Related]
10. The global campaign to eliminate HBV and HCV infection: International Viral Hepatitis Elimination Meeting and core indicators for development towards the 2030 elimination goals.
Popping S; Bade D; Boucher C; van der Valk M; El-Sayed M; Sigurour O; Sypsa V; Morgan T; Gamkrelidze A; Mukabatsinda C; Deuffic-Burban S; Ninburg M; Feld J; Hellard M; Ward J
J Virus Erad; 2019 Jan; 5(1):60-66. PubMed ID: 30800429
[TBL] [Abstract][Full Text] [Related]
11. Progress towards elimination of viral hepatitis by 2030 in the WHO Eastern Mediterranean Region, 2019.
Alaama AS; Khattabi H; Mugisa B; Atta H; Hermez J; Hutin YJ
Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):862-870. PubMed ID: 35817075
[TBL] [Abstract][Full Text] [Related]
12. Strengthening hepatitis B and C surveillance in Europe: results from the two global hepatitis policy surveys (2013 and 2014).
Lazarus JV; Mozalevskis A; Safreed-Harmon K; Eramova I
Hepatol Med Policy; 2016; 1():3. PubMed ID: 30288307
[TBL] [Abstract][Full Text] [Related]
13. The case for simplifying and using absolute targets for viral hepatitis elimination goals.
Polaris Observatory Collaborators
J Viral Hepat; 2021 Jan; 28(1):12-19. PubMed ID: 32979881
[TBL] [Abstract][Full Text] [Related]
14. Research gaps in viral hepatitis.
Boyd A; Duchesne L; Lacombe K
J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25054. PubMed ID: 29633564
[TBL] [Abstract][Full Text] [Related]
15. Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries.
Ishizaki A; Bouscaillou J; Luhmann N; Liu S; Chua R; Walsh N; Hess S; Ivanova E; Roberts T; Easterbrook P
BMC Infect Dis; 2017 Nov; 17(Suppl 1):696. PubMed ID: 29143609
[TBL] [Abstract][Full Text] [Related]
16. Changes to the national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs between 2013 and 2016: a cross-sectional survey of 34 European countries.
Maticic M; Zorman JV; Gregorcic S; Schatz E; Lazarus JV
Harm Reduct J; 2019 May; 16(1):32. PubMed ID: 31072401
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus elimination status and strategies in circumpolar countries, 2020.
Haering C; McMahon B; Harris A; Weis N; Lundberg Ederth J; Axelsson M; Olafsson S; Osiowy C; Tomas K; Bollerup S; Liitsola K; Archibald C; Blystad H; Bruce M; Nolen L
Int J Circumpolar Health; 2021 Dec; 80(1):1986975. PubMed ID: 34668463
[TBL] [Abstract][Full Text] [Related]
18. Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all.
Grebely J; Hajarizadeh B; Lazarus JV; Bruneau J; Treloar C;
Int J Drug Policy; 2019 Oct; 72():1-10. PubMed ID: 31345644
[TBL] [Abstract][Full Text] [Related]
19. Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries.
Ford N; Wiktor S; Kaplan K; Andrieux-Meyer I; Hill A; Radhakrishnan P; Londeix P; Forette C; Momenghalibaf A; Verster A; Swan T
Int J Drug Policy; 2015 Nov; 26(11):1088-93. PubMed ID: 26074094
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countries.
Maistat L; Kravchenko N; Reddy A
Hepatol Med Policy; 2017; 2():9. PubMed ID: 30288322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
